PharVision Advisers’s Keysight KEYS Stock Holding History

PharVision Advisers’s Portfolio KEYS Stock Details KEYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,091	Closed	-$313K	–	359
2025 Q1	$313K	Buy	+2,091	New	+$345K	0.43%	86

Other funds holding KEYS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

PharVision Advisers's KEYS Position: Q2 2025 in Review

PharVision Advisers sold out of Keysight (KEYS) in Q2 2025, closing a stake of 2,091 shares — an estimated $313K sold.

PharVision Advisers first reported a position in KEYS in Q1 2025 and held it in 1 quarter. The position peaked at $313K in Q1 2025. 878 funds tracked by Wall St. Rank hold KEYS as of Q2 2025.

PharVision Advisers reported no remaining Keysight position as of Q2 2025 after selling out during the quarter.
PharVision Advisers sold 2,091 Keysight shares in Q2 2025, an estimated $313K.
PharVision Advisers first reported a position in Keysight in Q1 2025 and held it in 1 quarter.
PharVision Advisers's Keysight position peaked at $313K in Q1 2025.
878 funds tracked by Wall St. Rank held Keysight as of Q2 2025.

Based on PharVision Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.